What is Odomzo (sonidegib) for?
Odomzo (sonidegib) is indicated for the treatment of patients with basal cell carcinoma which is locally advanced and which cannot be treated either by surgery or by radiotherapy1,2,3.
How does Odomzo (sonidegib) work?
The Hedgehog signalling pathway is a set of processes that control a number of cell activities including cell growth and correct development and differentiation. The active ingredient in Odomzo, sonidegib, attaches to a protein that controls the Hedgehog signalling pathway. By attaching to this protein, sonidegib blocks the Hedgehog signalling pathway, thereby reducing the growth and spread of cancer cells1.
The most common side effects are muscle spasms, hair loss, taste disturbance, tiredness, nausea, vomiting, muscle and bone pain, belly ache, headache, diarrhoea, weight loss, loss of appetite, and itching. Women who are pregnant or breastfeeding must not take Odomzo1.
Is Odomzo (sonidegib) approved?
Odomzo (sonidegib) was approved for the treatment of adults with locally advanced basal cell carcinoma (BCC) that cannot be treated with surgery or radiation therapy by:
- FDA (USA) on July 24, 20153
- EMA (EU) on August 14, 20151
- TGA (AUS) on December 19, 20162
How do I take Odomzo (sonidegib)?
The standard dosage is:
- One 200 mg capsule once a day at least 1 hour before and 2 hours after a meal.
Complete information about Odomzo (sonidegib) dosage and administration can be found in the resources section.
Note: Consult your treating doctor for personalised dosing.
Are there any known adverse reactions of Odomzo (sonidegib)?
Common adverse reactions
The most common adverse reactions (incidence ≥10%) listed in the prescribing information include:
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
Use in specific populations
As Odomzo (sonidegib) can be fatal for a fetus, pregnancy and breastfeeding is not advised during and for up to 20 months after the last dose.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.